Global Hemorrhagic Septicemia Vaccines Market Size Likely to Grow at a CAGR of 4.6% By 2035

The global hemorrhagic septicemia (HS) vaccines market is projected to reach USD 0.39 billion in 2026, and is expected to climb at a CAGR of 4.6% from 2026 to 2035, reaching USD 0.57 billion by 2035.

Hemorrhagic Septicemia Vaccines Market Revenue and Trends

Hemorrhagic septicemia vaccines are veterinary biological products intended for use in the prevention of acute, fatal, Pasteurella multocida serotype B:2 and E:2 haemorrhagic septicemia in livestock, mainly in cattle and buffaloes. They consist of inactivated, adjuvanted and multivalent vaccines that are used to help prevent high mortality outbreaks in dairy, beef and draft animals. The global hemorrhagic septicemia vaccines market is expanding at a steady pace, owing to the rising outbreaks of livestock diseases in endemic areas, growing demand for animal health products, escalating production of dairy and meat, government immunization programs for livestock, and development of better vaccines worldwide with regards to efficacy and duration of immunity.

What are the Factors That Have a Significant Contribution to the Growth of the hemorrhagic septicemia vaccines market?

With the expansion of the dairy and meat industries in the world, frequent outbreaks of the disease in Asia and Africa, and the high economic losses resulting from the disease, there is an increased demand for and adoption of effective livestock vaccines as essential preventive measures. There is consistent use of the market in routine immunization and outbreak control programs, which benefits the market, according to industry reports. With increasing intensity of livestock production and greater understanding of these animals' health, farmers, vets and governments are looking for cost-effective, reliable vaccines to complement good livestock management and ensure productivity and food security.

Advances in technology have led to the development of multivalent vaccines containing HS plus other common diseases of cattle, better adjuvants for longer duration of immunity, and thermostable vaccines which have increased field efficacy, storage capability in tropical environments and ease of use. Other factors are increased awareness of livestock disease control, greater availability of vaccines in emerging markets, and governments' efforts and investments in animal husbandry and disease eradication in developed and emerging markets.

Segment Insight

By Product Type

Inactivated hemorrhagic septicemia vaccines dominated the hemorrhagic septicemia vaccines market in 2025 due to their high immunity levels, availability, and proven safety, among other factors, and their use in national livestock vaccination programs. Strong growth from innovations in multivalent combinations for better overall herd immunity (a component of effective disease prevention and limitation of economic losses, widely considered by vets and livestock health experts as critical in endemic areas) is essential for smallholders and commercial farmers looking to benefit from cost-effective protection against deadly outbreaks.

By Distribution Channel

Pharmacies and online retail have the most market share as they provide consumers with the most convenient access points, availability of products, educational information, and secure delivery options. These channels are suitable for women or couples wishing to get pregnancy tested, or track their fertility, as they can get the product, as well as simple instructions on how to use it, and a place to get the product when needed. These are channels that health conscious consumers are most likely to select if they are seeking an over the counter fertility and pregnancy remedy.

Regional Insights

Asia Pacific is the largest region for the global market of hemorrhagic septicemia vaccines, with increasing livestock population, disease endemic in cattle and buffalo, government-supported vaccinations programs, and dairy and meat production as some of the key drivers. The area enjoys significant public animal health investment, significant smallholder farming populations, and stable market demand for animal health biologics for prevention.

The Asia Pacific region is also witnessing the most rapid expansion in the hemorrhagic septicemia vaccines market, due to the rising trend of livestock intensive farming, growing veterinary infrastructure, rising awareness of economic losses in the event of an outbreak, and supportive government policies. There has been a rise in the rollout of better and multivalent vaccines in countries such as India, Pakistan, China and Southeast Asian countries, which are also expanding their dairy sector and prioritising livestock productivity. The growth of animal husbandry and disease control programs further propel market growth in Asia Pacific.

Report Scope

Recent Developments

• In 2025: Indian Immunologicals Limited has introduced an advanced multivalent hemorrhagic septicemia vaccine with long duration of immunity, boosting its vaccine portfolio and providing extensive government and private sector immunization programmes in Asia.

List of the prominent players in the Hemorrhagic Septicemia Vaccines Market:

• Zoetis Inc.

• Merck Animal Health

• Boehringer Ingelheim Animal Health

• Elanco Animal Health

• Ceva Santé Animale

• Indian Immunologicals Limited

• Phibro Animal Health Corporation

• Intervac (PVT) Ltd

• Bio-Labs (PVT) Limited

• Brilliant Bio Pharma

• FATRO S.p.A.

• Vetoquinol S.A.

• National Veterinary Research Institute (NVRI)

• Institute of Animal Health and Veterinary Biologicals (IAH&VB)

• Others

The Hemorrhagic Septicemia Vaccines Market is segmented as follows:

By Vaccine Type

• Oil-adjuvant Inactivated Vaccines

  • Mineral Oil-adjuvant Bacterins

  • Montanide ISA-adjuvant Vaccines

  • Multi-emulsion Oil-adjuvant Formulations

• Aluminum Hydroxide-adjuvant Inactivated Vaccines

  • Alum-Precipitated Bacterins

  • Aluminium Hydroxide Gel Vaccines

  • Enriched Alum-Precipitated Formulations

• Live Attenuated Vaccines

  • Intranasal Live Attenuated Strains

  • Intramuscular Live Attenuated Strains (aroA Mutant Platforms)

• Other Vaccine Types

  • Subunit / Recombinant Protein Candidates

  • Combination Multivalent Vaccines

  • Thermostable Formulations

By Animal Type

• Cattle

  • Dairy Cattle

  • Draft Cattle

  • Beef Cattle

• Buffalo

  • Water Buffalo

  • Swamp Buffalo

• Other Animal Types

  • Pigs (Asia-specific outbreak contexts)

  • Sheep & Goats

By End User

• Veterinary Clinics & Hospitals

• Government Veterinary Programs

  • National Disease Control Campaigns

  • District-level Veterinary Dispensaries

• Research Institutes

• Other End Users

  • Commercial Dairy Enterprises

  • Livestock Cooperatives

By Distribution Channel

• Direct Sales (Government Tender Procurement)

• Distributors & Dealers

  • Veterinary Pharmaceutical Distributors

  • Cooperative Society Channels

• Online Retail

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America